- •Retinal Vein Occlusions
- •Preface
- •Acknowledgments
- •Contents
- •1.1 Anatomy and Histology
- •1.2 Microanatomy of the Retina
- •1.3 Vascular Anatomy
- •Bernoulli’s Principle and Deductions Concerning Changes in Central Retinal Vein Diameter at the Lamina Cribrosa
- •1.4 Pathologic Anatomy
- •1.4.1 Abnormalities of the Vessel Wall
- •1.4.2 Branch Retinal Vein Occlusion
- •1.4.3 Central Retinal Vein Occlusion
- •1.4.4 Hemicentral Retinal Vein Occlusion
- •1.5 Summary of Key Points
- •References
- •2.1 Abnormalities of the Blood
- •2.1.1 Thrombosis
- •2.1.2 Viscosity of Blood
- •2.2 Abnormalities of Blood Flow
- •2.2.1 Retinal Vascular Hemodynamics
- •2.2.1.1 Laplace’s Law
- •2.2.1.2 Poiseuille’s Law
- •A Misapplication of Poiseuille’s Law
- •2.2.1.3 Hemodynamics of Central Retinal Vein Occlusion
- •How Severe Must Central Venous Obstruction Be to Produce Symptoms?
- •The Central Retinal Artery in Central Retinal Vein Occlusion
- •2.2.1.4 Hemodynamics of BRVO
- •2.3 Macular Edema
- •2.3.1 Macular Anatomy and Its Relationship to Macular Edema in Retinal Vein Occlusion
- •2.3.2 Starling’s Law
- •2.3.3 The Retinal Pigment Epithelial Pump
- •2.3.4 Molecular Signaling in Macular Edema
- •Relevant Molecular Biologic Terminology
- •2.3.4.1 Vascular Endothelial Growth Factor
- •2.3.4.2 Other Retinal Cytokines with Lesser Roles
- •2.3.4.3 Molecular Signaling in BRVO
- •2.3.4.4 Molecular Signaling in CRVO
- •What Does the Response of RVO to Intravitreal Anti-VEGF Drugs Say About Pathophysiology?
- •2.4 Retinal Neovascularization
- •Spontaneous Venous Pulsations and CRVO
- •2.7 Animal Models of Retinal Vein Occlusion
- •2.7.1 Animal Models of BRVO
- •2.7.2 Animal Models of CRVO
- •2.8 Summary of Key Points
- •2.9 Future Directions
- •References
- •3.1 Background for Clinical Genetics
- •3.2 The Role of Polymorphisms in Genetic Studies
- •3.3 Types of Genetic Study Design
- •Why Are So Many Association Studies for Retinal Vein Occlusion Negative?
- •3.4 Studies of the Genetics of Retinal Vein Occlusion
- •3.4.1 Platelet Glycoprotein Receptor Genes
- •3.4.2.1 Pooled Retinal Vein Occlusion
- •3.4.2.2 Central Retinal Vein Occlusion
- •3.4.2.3 Branch Retinal Vein Occlusion
- •3.4.4 202210G > A Mutation of the Prothrombin Gene (Factor II Leiden)
- •3.4.6 Protein C
- •3.4.7 Protein S
- •3.4.8 Fibrinogen
- •3.4.9 Factor XII
- •3.4.12 Other Negative Genetic Association Studies
- •3.5 Summary of Key Points
- •References
- •4.1 Nosology of Retinal Vein Occlusions
- •4.2 Branch Retinal Vein Occlusion
- •4.3 Central Retinal Vein Occlusion
- •Central Retinal Vein Occlusion with Nonischemic and Ischemic Hemispheres
- •4.3.1 Conversion from Nonischemic to Ischemic Forms of Retinal Vein Occlusion
- •4.4 Summary of Key Points
- •References
- •Quantifying Risk
- •The Major Epidemiologic Studies of Retinal Vein Occlusion
- •5.2 Prevalence
- •5.2.1 Pooled Retinal Vein Occlusion
- •5.2.2 Branch Retinal Vein Occlusion
- •5.2.3 Central Retinal Vein Occlusion
- •5.2.4 Hemicentral Retinal Vein Occlusion
- •5.3 Incidence
- •5.3.1 Pooled Retinal Vein Occlusion
- •5.3.2 Branch Retinal Vein Occlusion
- •5.3.3 Central Retinal Vein Occlusion
- •5.4 Risk and Protective Factors for Retinal Vein Occlusion
- •5.4.1.1 Pooled Retinal Vein Occlusion
- •5.4.1.2 Branch Retinal Vein Occlusion
- •5.4.1.3 Central Retinal Vein Occlusion
- •5.4.1.4 Hemicentral Retinal Vein Occlusion
- •5.4.2 Gender
- •5.4.2.1 Pooled Retinal Vein Occlusion
- •5.4.2.2 Branch Retinal Vein Occlusion
- •5.4.2.3 CRVO
- •5.4.2.4 Hemicentral Retinal Vein Occlusions
- •5.4.3 Race
- •5.4.4 Laterality
- •5.4.5 Body Mass Index
- •5.4.6 Education
- •5.4.7 Physical Activity
- •5.4.8 Miscellaneous Factors Explored and Not Found Important
- •5.5.1 Pooled Retinal Vein Occlusion
- •5.5.2 Branch Retinal Vein Occlusion
- •5.5.3 Central Retinal Vein Occlusion
- •5.5.4 Hemicentral Retinal Vein Occlusion
- •5.6 Life Expectancy
- •5.7 Visual Impact of Retinal Vein Occlusions
- •5.8 Summary of Key Points
- •References
- •6.1 Introduction
- •6.2 Systemic Associations
- •6.2.1 Hypertension
- •6.2.1.1 Pooled Retinal Vein Occlusions
- •6.2.1.2 Branch Retinal Vein Occlusion
- •6.2.1.3 Central Retinal Vein Occlusion
- •6.2.2 Diabetes Mellitus
- •6.2.2.1 Pooled Retinal Vein Occlusion
- •6.2.2.2 Branch Retinal Vein Occlusion
- •6.2.2.3 Central Retinal Vein Occlusion
- •6.2.3 Hyperlipidemia
- •6.2.3.1 Pooled Retinal Vein Occlusions
- •6.2.3.2 Branch Retinal Vein Occlusion
- •6.2.3.3 Central Retinal Vein Occlusion
- •6.2.4 Cardiovascular Disease
- •6.2.4.1 Pooled Retinal Vein Occlusion
- •6.2.4.2 Branch Retinal Vein Occlusion
- •6.2.4.3 Central and Hemicentral Retinal Vein Occlusion
- •6.2.4.4 Stroke
- •6.2.4.5 Carotid Artery Disease and Peripheral Vascular Disease
- •6.2.5 Rheologic and Hematologic Abnormalities
- •6.2.6 Coagulation Abnormalities
- •6.2.6.1 Antiphospholipid Antibodies
- •6.2.6.2 Factor VII
- •6.2.6.3 Factor VIII
- •6.2.6.4 Lipoprotein a
- •6.2.6.5 Von Willebrand Factor
- •6.2.6.6 Other Coagulation Factors
- •6.2.7 Hyperhomocysteinemia
- •6.2.7.1 Pooled Retinal Vein Occlusion
- •6.2.7.2 Branch Retinal Vein Occlusion
- •6.2.7.3 Central and Hemicentral Retinal Vein Occlusion
- •6.2.8 Serum Folate
- •6.2.9 Serum B12
- •6.2.10 Smoking
- •6.2.11 Alcohol Consumption
- •6.2.14 No Underlying Vascular Risk Factor
- •6.3 Ocular Associations
- •6.3.1 Pooled Retinal Vein Occlusion
- •6.3.2 Branch Retinal Vein Occlusion
- •6.3.3 Central Retinal Vein Occlusion and Hemicentral Retinal Vein Occlusion
- •6.4 Practical Recommendations About the Systemic Workup of Patients with Retinal Vein Occlusion
- •History of the Standard Workup for Systemic Associations in Central Retinal Vein Occlusion
- •6.5 Retinal Vein Occlusion and Cardiovascular Disease Risk
- •6.6 Differences in Systemic Associations Between Ischemic and Nonischemic CRVOs
- •6.7 Summary of Key Points
- •References
- •7.1 Branch Retinal Vein Occlusion
- •7.1.1 Acute Phase
- •7.1.1.1 Symptoms
- •7.1.2 Clinical Signs
- •7.1.2.1 Visual Acuity
- •7.1.3 Chronic Phase
- •7.1.3.1 Clinical Signs
- •7.1.3.2 Visual Acuity
- •Why Does the Visual Outcome in Nonischemic, Macula-Involving Branch Retinal Vein Occlusions Usually Vary with the Size of the Involved Retina?
- •7.2 Central Retinal Vein Occlusion
- •7.2.1 Acute Phase
- •7.2.1.1 Symptoms
- •7.2.1.2 Clinical Signs
- •When Retinal Venous Congestion and Optic Disc Edema Are Not Central Retinal Vein Occlusion
- •What Is the Relationship of Central Retinal Artery Pressure and Cilioretinal Artery Pressure?
- •Retinal Whitening Does Not Equal Infarction
- •A Clinical Picture Predicted by a Hypothesis
- •7.2.1.3 Visual Acuity
- •7.2.2 Chronic Phase
- •Why Are Optic Disc Collaterals Associated with Worse Initial and Final Visual Acuity After CRVO?
- •7.2.2.1 Visual Acuity
- •7.3 Hemicentral Retinal Vein Occlusion
- •7.3.1 Clinical Signs
- •7.3.2 Visual Acuity
- •7.4 Summary of Key Points
- •References
- •Which Measure of Reproducibility Is Best?
- •8.1 Color Fundus Photography
- •8.2 Fluorescein Angiography
- •8.2.1 Branch Retinal Vein Occlusion
- •8.2.2 Central Retinal Vein Occlusion
- •8.3 Optical Coherence Tomography and the Retinal Thickness Analyzer
- •Methods of Analysis of OCT in RVO
- •8.4 Visual Field Testing
- •8.5 Electroretinography
- •Electroretinography Essentials for Retinal Vein Occlusions
- •8.5.1 Branch Retinal Vein Occlusion
- •8.5.2 Central Retinal Vein Occlusion
- •8.5.3 Hemicentral Retinal Vein Occlusion
- •8.6 Indocyanine Green Angiography
- •8.7 Color Doppler Ultrasonographic Imaging
- •8.8 Laser Doppler Flowmetry
- •8.9 Ophthalmodynamometry
- •8.10 Scanning Laser Doppler Flowmetry
- •8.11 Laser Interferometry to Measure Pulsatile Choroidal Blood Flow
- •8.12 Vitreous Fluorophotometry
- •8.13 Summary of Key Points
- •References
- •9.1 Terminology
- •9.2 Branch Retinal Vein Occlusion
- •9.3 Central Retinal Vein Occlusion
- •9.3.1 Clinical Characteristics
- •In the Face of Evidence that Fluorescein Angiography Is Poorly Predictive of Ischemia in Acute Central Retinal Vein Occlusion, Why Is It Widely Used?
- •9.3.2 Conversion from Nonischemic to Ischemic Central Retinal Vein Occlusion
- •9.3.3 Outcomes by Ischemic Status
- •9.4 Interaction of Ischemia with Effects of Treatments
- •9.4.1 Branch Retinal Vein Occlusion
- •9.4.2 Central Retinal Vein Occlusion
- •9.5 Summary of Key Points
- •References
- •10.1 Branch Retinal Vein Occlusion
- •10.2 Central Retinal Vein Occlusion
- •10.3 Hemicentral Retinal Vein Occlusion
- •10.4 Treatment of Posterior Segment Neovascularization in Retinal Vein Occlusion
- •10.5 Summary of Key Points
- •References
- •11.1 The Pathoanatomy and Pathophysiology of Iris and Angle Neovascularization
- •11.2 Clinical Picture of Anterior Segment Neovascularization
- •11.4 Anterior Segment Neovascularization in Branch Retinal Vein Occlusion
- •11.5 Anterior Segment Neovascularization in Central Retinal Vein Occlusion
- •The Problem of Undetected Anterior Segment Neovascularization After Central Retinal Vein Occlusion
- •Why Is Anterior Segment Neovascularization Less Common in Central Retinal Vein Occlusion Than in Central Retinal Artery Occlusion?
- •11.6 Anterior Segment Neovascularization in Hemicentral Retinal Vein Occlusion
- •11.7 Summary of Key Points
- •References
- •12.1 Branch Retinal Vein Occlusion with Macular Edema
- •12.2 Central Retinal Vein Occlusion with Macular Edema
- •12.3 Summary of Key Points
- •References
- •Visual Acuity Measurement in Treatment Studies
- •OCT Measurement of Macular Thickness in Treatment Studies
- •13.1 Medical Treatment of Retinal Vein Occlusion
- •13.1.1 Anticoagulation
- •13.1.2 Systemic Thrombolytic Therapy
- •13.1.3 Isovolumic Hemodilution
- •Recipe for Isovolumic Hemodilution
- •13.1.4 Plasmapheresis
- •13.2 Treatment of Previously Unsuspected Risk Factors for Retinal Vein Occlusion
- •13.3.1 Treatments for Macular Edema
- •Relative Corticosteroid Potencies
- •13.3.2 Treatments for Intraocular Neovascularization
- •13.4 Results of Clinical Studies of Treatments for Macular Edema Secondary to Retinal Vein Occlusions
- •13.4.1 Branch Retinal Vein Occlusion
- •13.4.1.1 Grid Laser
- •13.4.1.2 Subthreshold Grid Laser Treatment
- •13.4.1.3 Sector Panretinal Laser Photocoagulation
- •13.4.1.5 Posterior Subtenon’s Triamcinolone
- •13.4.1.6 Intravitreal Corticosteroids
- •13.4.1.7 Combination Treatments Involving Intravitreal Triamcinolone Injections
- •13.4.1.8 Arteriovenous Sheathotomy
- •13.4.1.9 Vitrectomy
- •13.4.1.10 Intravitreal Injection of Autologous Plasmin
- •13.4.2 Central Retinal Vein Occlusion
- •13.4.2.2 Combination Regimen: Bevacizumab, Panretinal Laser, and Grid Laser
- •13.4.2.3 Systemic Corticosteroids
- •13.4.2.4 Posterior Subtenon’s Triamcinolone Injection
- •13.4.2.5 Intravitreal Corticosteroids
- •13.4.2.6 Vitrectomy
- •13.5 Treatment of Intraocular Neovascularization
- •13.5.1 Sector Panretinal Laser Photocoagulation for Retinal and Disc Neovascularization After Branch Retinal Vein Occlusion
- •13.5.2 Vitrectomy for Intraocular Neovascularization with Vitreous Hemorrhage
- •13.5.3 Laser Panretinal Photocoagulation for Anterior Segment Neovascularization
- •13.6 Economic Considerations
- •13.7 Future Directions
- •13.8 Summary of Key Points
- •References
- •14.1 Pooled Retinal Vein Occlusions in the Young
- •14.2 Branch Retinal Vein Occlusion in Younger Patients
- •14.3 Central Retinal Vein Occlusion in Younger Patients
- •14.4 Workup in the Younger Patient with Retinal Vein Occlusion
- •14.5 Summary of Key Points
- •References
- •15.1 Failed and Unadopted Treatments for Branch Retinal Vein Occlusion
- •15.1.1 Sector Panretinal Laser Photocoagulation for Serous Retinal Detachment in Branch Retinal Vein Occlusion
- •15.1.2 Laser Chorioretinal Venous Anastomosis for Branch Retinal Vein Occlusion with Macular Edema
- •15.1.3 Intravenous Infusion of Tissue Plasminogen Activator
- •15.1.4 Intravitreal Injection of Tissue Plasminogen Activator
- •15.1.5 Macular Puncture for Branch Retinal Vein Occlusion with Macular Edema
- •15.2 Failed and Unadopted Treatments for Central Retinal Vein Occlusion
- •15.2.1 Grid Laser for Macular Edema in Central Retinal Vein Occlusion
- •15.2.2 Chorioretinal Venous Anastomosis for Nonischemic Central Retinal Vein Occlusion with Macular Edema
- •15.2.3 Radial Optic Neurotomy for Central Retinal Vein Occlusion
- •15.2.4 Retinal Endovascular Surgery with Intravenous Injection of Tissue Plasminogen Activator
- •15.2.5 Intravitreal Injection of Tissue Plasminogen Activator
- •15.2.6 Intravitreal Tissue Plasminogen Activator and Triamcinolone
- •15.2.7 Systemic Acetazolamide for Central Retinal Vein Occlusion with ME
- •15.2.8 Combined Central Retinal Vein Occlusion and Central Retinal Artery Occlusion
- •15.2.9 Optic Nerve Sheath Decompression
- •15.2.10 Section of the Posterior Scleral Ring
- •15.2.11 Infusion of High Molecular Weight Dextran
- •15.3 Failed and Unadopted Treatments for HCRVO
- •15.4 Summary of Key Points
- •References
- •16.1 Case 16.1: An Asymptomatic Central Retinal Vein Occlusion with Asymmetric Hemispheric Involvement
- •16.1.1 Discussion
- •16.2 Case 16.2: Chronic Macular Branch Vein Occlusion with Subtle Ophthalmoscopic Signs, More Obvious Fluorescein Angiographic Signs, and Macular Edema
- •16.2.1 Discussion
- •16.3 Case 16.3: Old Hemicentral Retinal Vein Occlusion with Late Vitreous Hemorrhage and Hyphema
- •16.3.1 Discussion
- •16.4 Case 16.4: Spontaneous Improvement of a Nonischemic Central Retinal Vein Occlusion
- •16.4.1 Discussion
- •16.5 Case 16.5: Conversion of a Nonischemic Hemicentral Retinal Vein Occlusion to an Ischemic One
- •16.5.1 Discussion
- •16.6 Case 16.6: Nonarteritic Ischemic Optic Neuropathy Following Branch Retinal Vein Occlusion
- •16.6.1 Discussion
- •16.7 Case 16.7: Differentiating Central Retinal Vein Occlusion from the Ischemic Ocular Syndrome
- •16.7.1 Discussion
- •16.8 Case 16.8: Late Development of Neovascularization Elsewhere After Ischemic Branch Retinal Vein Occlusion
- •16.8.1 Discussion
- •16.9 Case 16.9: Nonischemic Central Retinal Vein Occlusion with Secondary Branch Retinal Artery Occlusion
- •16.9.1 Discussion
- •16.10 Case 16.10: Nonischemic Central Retinal Vein Occlusion with Macular Edema or Asymmetric Diabetic Retinopathy with Diabetic Macular Edema?
- •16.10.1 Discussion
- •16.11 Summary of Key Points
- •References
- •Index
252 |
11 Anterior Segment Neovascularization in Retinal Vein Occlusion |
11.2Clinical Picture of Anterior Segment Neovascularization
Anterior segment neovascularization (ASNV) is comprised of neovascularization of the iris (NVI), also called rubeosis iridis, and neovascularization of the angle (NVA).22 Whereas normal iris vessels follow a regular radial path, iris new vessels are tortuous and irregular.22 ASNV starts separately at the pupillary margin and the iris base. In CRVO, it is detectable first at the pupillary margin (in approximately 88% of cases) and later at the iris base or in the angle.55 However, in approximately 12% of cases, NVA precedes NVI after ischemic CRVO.11 With further growth, a network develops that connects the two initiating regions of NVI.22 Eventually, a vascular membrane develops that causes peripheral anterior synechiae and ectropion uvea.22 Iris new vessels have thin walls in comparison to the thicker walls of normal iris veins. In severe cases, a vascular membrane covers the pupil producing seclusion pupillae.22
The frequency of detection of ASNV depends on the method used. Slit lamp biomicroscopy is the least sensitive, iris and angle fluorescein angiography are more sensitive, and histopathological examination of surgical specimens or postmortem tissue is the most sensitive.22 Dilation of the pupil makes detection of NVI more difficult (Figs. 11.4 and 11.5).9,69 Nonspecific fluorescein leakage on iris fluorescein angiography can be seen in the elderly, but can be distinguished from the more prominent leakage associated with NVI.46
Clinical detection of NVI is clouded by the difficulty of distinguishing dilated normal iris vessels from NVI. Eyes with inflammation can have dilated iris vessels that may masquerade as NVI. Iris neovascularization must also be distinguished from iris vascular tufts which are located along the pupillary margin and do not occur on the surface of the iris stroma or in the angle.13,14 Iris vascular tufts have been associated with aging, diabetes, myotonic dystrophy, and rarely RVO (Fig. 11.6).49
Iris color influences the ease of detection of NVI.54 Clinical detection at the slit lamp is easier
Fig. 11.4 In the undilated state, NVI is shown (arrowhead)
Fig. 11.5 In the dilated state, the NVI cannot be detected
in a light-colored iris.22 Subtle NVI may be difficult to discern in a dark-colored iris.45 Redfree light may make detection of the red NVI easier.16 In difficult cases, iris fluorescein angiography and gonioangiography can make detection of NVI and NVA easier.24,53 Iris fluorescein angiography is more sensitive than slit lamp biomicroscopy in the detection of NVI and NVA, but is also less specific.6,53,59 Dilated iris vessels in eyes with iritis, normal iris vessels in older patients, and eyes of diabetics with retinopathy, but no NVI, can leak fluorescein on angiography just as does NVI. Therefore, iris fluorescein angiography is not always a reliable method for distinguishing NVI and NVA.34,37,77,78
Figures 11.7, 11.8 and 11.9 show standards useful in interpreting iris fluorescein angiograms.
11.3 Classification of Anterior Segment Neovascularization |
253 |
|
a |
b |
c |
d |
e |
Fig. 11.6 Images from an eye mistakenly thought to have iris neovascularization but having an iris vascular hamartoma instead. This 71-year-old man woke up with blurred vision in the left eye and was found to have visual acuity of 20/50 of the left eye, an intraocular pressure of 38, and a hyphema. The patient’s ophthalmologist thought that neovascularization was present at 8 o’clock on the pupillary margin and made a provisional diagnosis of ischemic ocular syndrome. A carotid Doppler study was scheduled, and the patient was referred to the author for panretinal photocoagulation. There was no evidence of ischemic ocular syndrome. Rather, the lesion at the 8 o’clock pupillary margin was an iris vascular hamartoma which had bled spontaneously. (a) Slit lamp photograph showing a mulberry-type red lesion at the pupillary margin (the black arrow). (b) Magnified slit
lamp photograph of the iris vascular hamartoma (blue oval). Neovascularization of the iris associated with ischemic retinopathies is flat and forms an irregular, lacy network on the surface of the iris, not a discrete, elevated lesion. (c) The fundus photograph of this eye showed no ischemic signs. An insignificant and unrelated epiretinal membrane is present (the black arrow). (d) A frame from the early-phase fluorescein angiogram (25 s) shows normal arterial filling. (e) A frame from the mid-phase fluorescein angiogram (34 s) shows normal venous filling. The carotid Doppler study was normal. The hyphema cleared in a few days during which the intraocular pressure was controlled with topical hypotensive drops. The patient was educated that occasional anterior chamber hemorrhages were a possibility and was advised to return if a similar episode reoccurred
11.3Classification of Anterior Segment Neovascularization
Several classification schemes for NVI have been proposed, and none is accepted by the majority of clinicians (Table 11.2).7,24,66,67 There are also different classification schemes for the clinical and histopathologic stages of NVA (Table 11.3 and
Fig. 11.10).38,51,53 The purpose of these schemes is to attempt to provide a prognosis for visual outcome. They differ not only in conception but also in the method used for detecting NVI and NVA. Although standardized classifications have attraction to researchers, the relative uncommonness of NVI makes the ability to recall details of any system difficult for the clinician, and the author favors a method of straightforward
254 |
11 Anterior Segment Neovascularization in Retinal Vein Occlusion |
Fig. 11.7 Example of a normal iris fluorescein angiogram. No dye leakage is present, although in patients over the age of 50 years, a small amount of pupillary margin leakage of fluorescein can be considered normal (Reprinted with permission from Bandello et al.7)
Fig. 11.9 Example of iris neovascularization present around the entire pupillary margin and at several places on the iris stroma (Reprinted with permission from Bandello et al.7)
description of pupillary margin and angle involvement by neovascularization as being most practical (Figs. 11.11 and 11.12).
Fig. 11.8 Example of nonproliferative diabetic iridopathy. Dye leakage is prominent in the late phase, but neovascularization is absent (Reprinted with permission from Bandello et al.7)
11.4Anterior Segment Neovascularization in Branch Retinal Vein Occlusion
Anterior segment neovascularization is less common after ischemic BRVO than ischemic CRVO because the area of capillary nonperfusion is smaller. Nevertheless, ASNV can occur after BRVO.12 In the Standard Care Versus Corticosteroid for Retinal Vein Occlusion (SCORE) BRVO study, the 36-month incidence of NVI and NVG were 0.3% and 2.2%, respectively.12 In one large case series, NVI developed in 1.6% of cases of major BRVO.25 NVA developed in 0.5% of cases of major BRVO.25 Treatment with intravitreal triamcinolone did not reduce the incidence of ASNV after BRVO in the SCORE BRVO study.12
Grading systems for neovascularization of the iris
|
|
Grades |
|
|
|
Reference |
Detection method |
0 |
1 |
2 |
3 |
Teich and Walsh67; |
Slit lamp |
Pupillary margin NVI <2 |
Pupillary margin NVI > 2 |
Ciliary zone NVI or ectropion |
Ciliary zone NVI or ectropion |
Weiss and Gold79 |
biomicroscopy |
quadrants |
quadrants |
uvea of 1–3 quadrants |
uvea of four quadrants |
Bandello et al.7 |
Iris FA |
No fluorescein leakage |
Dilated iris capillaries that |
Pupillary margin or stromal |
New vessels in the angle with |
|
|
|
leak fluorescein |
new vessels that leak |
elevated IOP |
|
|
|
|
fluorescein |
|
Tauber et al.66 |
Slit lamp biomicros- |
One quadrant involved; |
Two quadrants involved; |
Three quadrants involved; |
Four quadrants involved; |
|
copy and gonioscopy |
pupillary margin, iris |
pupillary margin, iris |
pupillary margin, iris stroma, |
pupillary margin, iris stroma, |
|
|
stroma, and angle |
stroma, and angle |
and angle involvement |
and angle involvement |
|
|
involvement graded |
involvement graded |
graded |
graded |
|
|
|
|
|
|
Not all the grading systems use the same numbering. Some start at zero and some start at one. For comparison purposes, they have all been converted to a scale starting at zero. Ciliary zone – the outer zone of the iris separated from the pupillary zone by the collarette
Grading systems for neovascularization of the angle
|
|
Grades |
|
|
|
Reference |
Detection method |
0 |
1 |
2 |
3 |
Teich and Walsh67; |
Slit lamp biomicroscopy |
NV twigs cross the scleral spur |
NV twigs cross the scleral spur |
PAS of 1–3 quadrants |
PAS of four quadrants |
Weiss and Gold79 |
|
£2 quadrants |
>2 quadrants |
|
|
Little et al.44 |
Slit lamp gonioscopy |
Few or no PAS without |
Few or many PAS with |
360° closed-angle |
|
|
|
glaucoma |
glaucoma |
|
|
Ohnishi et al.53 |
Fluorescein |
Hyperfluorescent dots in the |
Hyperfluorescent line in the |
Hyperfluorescent |
Peripheral anterior |
|
gonioangiography |
angle |
angle perpendicular to the |
network spreads over |
synechia present |
|
|
|
iris root |
the trabecular |
|
|
|
|
|
meshwork |
|
|
|
|
|
|
|
Not all the grading systems use the same numbering. Some start at zero and some start at one. For comparison purposes, they have all been converted to a scale starting at zero
Occlusion Vein Retinal Branch in Neovascularization Segment Anterior 4.11
255
256 |
11 Anterior Segment Neovascularization in Retinal Vein Occlusion |
Fig. 11.10 Classification of neovascularization of the angle using fluorescein gonioangiography for detection. In grade 1, dot proliferations are seen at the iris root. In grade 2, a linear vessel arising from these dot proliferations rises at a perpendicular to the iris root to connect to the trabecular meshwork. In grade 3, an arborization of the vessel over the surface of the trabecular meshwork is seen. In grade 4, contracture of the neofibromyovascularization occurs with synechia (Redrawn from Ohnishi53)
Fig. 11.12 A 71-year-old man with diabetes mellitus and hypertension developed a CRVO of the left eye and NVI which did not regress despite laser PRP. At the time of this slit lamp photograph, the visual acuity was NLP, the intraocular pressure was 54, and he was comfortable. Note that NVI is in various stages of development in different regions of the iris. NVI typically begins at the pupillary margin (the yellow arrows) and iris base (the black arrows). The zone of iris stroma is usually uninvolved at an earlier stage (the green oval) but becomes involved later (the blue oval). Eventually, the fibrovascular membrane on the surface of the iris contracts, inducing ectropion uvea (purple arrows, compare absence at yellow arrows)
a
Fig. 11.11 Slit lamp images of an 88-year-old man with primary open-angle glaucoma who developed an ischemic central retinal vein occlusion that evolved to anterior segment neovascularization and neovascular glaucoma. The eye received intravitreal bevacizumab injection and laser panretinal photocoagulation but eventually lost all vision despite therapy. (a) The elevated intraocular pressure has
b led to corneal microcystic edema indicated by the irregular light reflex (the black arrow). The iris new vessels begin at the pupillary margin, next involve the angle (not shown) and eventually spread across the iris stroma (the green arrow), remaining densest near the pupillary margin. (b) The eye is inflamed with injected conjunctiva (the black arrow) and posterior synechia to the lens capsule (the blue arrow). The mesh of neovascularization on the iris surface (the turquoise arrow) eventually will retract and cause ectropion uvea (not shown)
